Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.

PloS one - 1 Jan 2018

Plagnol Vincent, Woodhouse Samuel, Howarth Karen, Lensing Stefanie, Smith Matt, Epstein Michael, Madi Mikidache, Smalley Sarah, Leroy Catherine, Hinton Jonathan, de Kievit Frank, Musgrave-Brown Esther, Herd Colin, Baker-Neblett Katherine, Brennan Will, Dimitrov Peter, Campbell Nathan, Morris Clive, Rosenfeld Nitzan, Clark James, Gale Davina, Platt Jamie, Calaway John, Jones Greg, Forshew Tim

Abstract excerpt

Circulating tumor DNA (ctDNA) analysis is being incorporated into cancer care; notably in profiling patients to guide treatment decisions. Responses to targeted therapies have been observed in patients with actionable mutations detected in plasma DNA at variant allele fractions (VAFs) below 0.5%. Highly sensitive methods are therefore required for optimal clinical use. To enable objective assessment of assay...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Cohort Studies

Share to Liquid Biopsy

Share to Polymerase Chain Reaction

Share to Reproducibility of Results

Share to Sensitivity and Specificity

Share to Sequence Analysis, DNA

Source

Open in PubMed Open full text

Identifiers

PMID: 29543828
DOI: 10.1371/journal.pone.0193802
PMCID: PMC5854321

Genes

ALK
EGFR
ERBB2
FGFR1
MET
ROS1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling.PMID 29543828Read ↗

Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNASemantic proximity Read ↗

Analytical and Clinical Validation of an Amplicon-based Next Generation Sequencing Assay for Ultrasensitive Detection of Circulating Tumor DNASemantic proximity Read ↗

Analytical and Clinical Validation of a Highly Sensitive NGS-Based ctDNA Assay with Real-World Concordance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Outcomes in oncogenic-addicted advanced NSCLC patients with actionable mutations identified by liquid biopsy genomic profiling using a tagged amplicon-based NGS assay.Semantic proximity Read ↗

Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA.Semantic proximity Read ↗

Validation of a DNA-Based Next-Generation Sequencing Test for Molecular Diagnostic Variant and Fusion Detection in Formalin-Fixed, Paraffin-Embedded Tissue Specimens and Liquid Biopsy Plasma/Cell-Free DNA Samples.Semantic proximity Read ↗

Validation of a liquid biopsy assay with molecular and clinical profiling of circulating tumor DNASemantic proximity Read ↗

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer PatientsSemantic proximity Read ↗

Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.Semantic proximity Read ↗

Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencerSemantic proximity Read ↗

Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patientsSemantic proximity Read ↗

Routine Molecular Screening of Patients with Advanced Non-SmallCell Lung Cancer in Circulating Cell-Free DNA at Diagnosis and During Progression Using OncoBEAMTM EGFR V2 and NGS Technologies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.